Amgen: Neutropenia trials

The registry lists 10 Neutropenia studies with Amgen as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 2 3Phase 3 2Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk ChemotherapyCompletedNCT02178475Results posted
• Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.CompletedNCT01813721Results posted
• PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation StudyCompletedNCT00911170Phase 3Results posted
• A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic ChemotherapyCompletedNCT00883181Results posted
• A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With CancerCompletedNCT00277160Phase 4
• FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive ChemotherapyCompletedNCT00125723Phase 4
• Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)CompletedNCT00115414Phase 2
• Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving ChemotherapyCompletedNCT00035620Phase 2
• Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving ChemotherapyCompletedNCT00035594Phase 3
• A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.CompletedNCT00002126Phase 2